Touching Base

Latest Episodes:

Restoring Hearing Loss, CAR T Manufacturing, DNA-Based Medicines, Nvidia and Recursion; Eric Topol Jan 26, 2024

Show notes

Episode 6 (January 26, 2024): 11-year-old regains hearing after gene therapy; Kyverna uses blood draw instead of apheresis for CAR T manufacturing; DNA production technology with GSK and Elegen, StockWatch with Nvidia and Recursion; an interview with renowned cardiologist, Eric Topol, MD

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

Gene Therapy Restores Hearing in 11-Year-Old After Just One Month

GEN, January 24th, 2024

GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines

By Jonathan Grinstein, GEN Edge, January 24th, 2024

Blood Brothers: Kyverna Reinvents Autologous CAR T Manufacturing from Blood Draw

By Jonathan Grinstein, GEN Edge, January 24th, 2024

StockWatch: Nvidia Jumps 24% on Recursion, Amgen AI Partnerships

By Alex Philippidis, GEN Edge, January 21st, 2024

Five Deaf Children Have Hearing Restored by AAV-Based Gene Therapy

GEN, January 25th, 2024

Hosted on Acast. See acast.com/privacy for more information.

Alzheimer’s Disease, Monkey Cloning, Cytokinetics Stock; Jen Nwankwo Jan 18, 2024

Show notes

Episode 5 (January 19, 2024); RNAs to address Alzheimer’s disease; monkey cloned via somatic cell nuclear transfer; Cytokinetics stock roller coaster; an interview with founder and CEO of 1910 Genetics, Jen Nwankwo, PhD.

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

· Alzheimer’s Disease Linked to Toxic Short RNAs

GEN, January 18, 2024.

· Rhesus Monkey Cloned via Somatic Cell Nuclear Transfer

GEN, January 16, 2024.

· StockWatch: M&A Talk Fuels Cytokinetics Stock Roller Coaster

By Alex Philippidis, GEN Edge, January 16th, 2024.

Hosted on Acast. See acast.com/privacy for more information.

J.P. Morgan 2024: Illumina, 10x, Danaher, AI; Liberate Bio Jan 11, 2024

Show notes

Episode 4 (January 12, 2024): Takeaways from the J.P. Morgan Health Care conference: Illumina, Danaher, 10x, Empress Therapeutics; an interview with Liberate Bio’s Shawn Davis and Walter Strapps.

Listed below are references to relevant GEN stories discussed in this episode of Touching Base:

JPM: Illumina’s new CEO spells out 2024 priorities, presents preliminary Q4 2023 results

By Alex Philippidis, GEN, January 10, 2024.

JPM: Prime Medicine eyes 2024 IND for first prime editing therapy

By Alex Philippidis, GEN, January 9, 2024

JPM 2024: Veracyte’s C2i genomics acquisition adds AI readouts to liquid biopsy testing

By Jonathan D. Grinstein, GEN, January 8, 2024

JPM: More M&A “firepower” in store for 2024, EY predicts

By Alex Philippidis, GEN, January 8, 2024

Hosted on Acast. See acast.com/privacy for more information.

Novartis and Voyager, JPM Ahead, Epigenetic Engineering; Alex Aravanis Jan 05, 2024

Show notes

Episode 3 (January 5, 2024): Interview with Co-founder and CEO of Moonwalk Biosciences and former CTO of Illumina, Alex Aravanis; Neuro gene therapy with Novartis and Voyager; GEN reporters look forward to the 2024 J.P. Morgan Healthcare Conference

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

Novartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration

By Alex Philippidis, GEN, January 2, 2024.

Moonwalk Biosciences Raises $57M to Edit the Epigenome

By Uduak Thomas, GEN, January 4, 2024.

Hosted on Acast. See acast.com/privacy for more information.

Launch of Tome Biosciences, AI scientist, mRNA vaccines Dec 21, 2023

Show notes

Episode 2 (December 22, 2023): Interview with President and CEO of Tome Biosciences, Rahul Kakkar; intelligent lab partner using LLMs; AI for antimicrobials; mRNA vaccine production in Africa; Moderna’s positive cancer vaccine data.

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M By Alex Philippidis, GEN, December 19, 2023.
Artificial Intelligence-Based Lab Partner Designs, Runs Experiments in the Lab GEN, December 20, 2023.
BioNTech Advances Plans for mRNA Vaccine Production in Africa by 2025 GEN, December 19, 2023.
Explainable AI Directs Small Molecule Structural Class Drug Discovery By Jonathan Grinstein, GEN, December 20, 2023.
StockWatch: Positive Cancer Vaccine Data Wows Moderna Investors By Alex Philippidis, GEN Edge, December 18, 2023.

Hosted on Acast. See acast.com/privacy for more information.

Autism, AI and Epigenetics; Nevan Krogan Dec 08, 2023

Show notes

Episode 1 (Week ending December 8, 2023): Nevan Krogan (UCSF) mapping autism pathways; Nvidia’s latest AI partnership; CAR-T regulations; epigenome editing; mRNA therapeutics.

References to the GEN stories, media and other items discussed in this episode of Touching Base:

· Autism’s Molecular Mechanisms Uncovered through Protein-Protein Interaction Network

By Julianna Lemieux, GEN, December 5, 2023.

· Rhapsody in B: Tune Therapeutics Presents Data for Hepatitis B Epigenetic Silencer

By Jonathan Grinstein, GEN Edge, December 6, 2023.

· Nvidia Looks to Genentech for its Next Leap in AI Drug Discovery

By Alex Philippidis, GEN Edge, November 28, 2023.

· StockWatch: CAR-T Shares Mostly Flat as FDA Probes Risk of New Cancers

By Alex Philippidis, GEN, December 1, 2023

· Perfect Pitch: Genome Editing Pioneer Fyodor Urnov on Commercializing CRISPR Therapies and Epigenomic Tuning {VIDEO}

GEN Edge, August 30, 2023

· Press release: John Crowley appointed President & CEO of BIO